Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2026-01-01 @ 12:13 AM
Study NCT ID:
NCT06974058
Status:
COMPLETED
Last Update Posted:
2025-12-19
First Post:
2025-05-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
Sponsor:
Liaquat University of Medical & Health Sciences
Organization:
Study Overview
Official Title:
Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.
Status:
COMPLETED
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
Detailed Description:
Long COVID-19, characterized by persistent symptoms lasting weeks or months after the acute phase of SARS-CoV-2 infection, presents a significant challenge for healthcare systems and affected individuals. Common symptoms include fatigue, brain fog, muscle pain, joint pain, sleep disturbances, and generalized weakness. Despite extensive research, there are limited effective therapeutic options for managing Long COVID-19 symptoms.
Quercetin and curcumin, two natural compounds with well-documented anti-inflammatory, antioxidant, and immunomodulatory properties, have gained attention for their potential benefits in various inflammatory and infectious conditions. Quercetin, a flavonoid found in various fruits and vegetables, has been shown to inhibit pro-inflammatory cytokines, reduce oxidative stress, and modulate immune responses. Curcumin, a polyphenol derived from turmeric (Curcuma longa), is known for its strong anti-inflammatory and antioxidant properties and has demonstrated immune-modulating effects in clinical studies.
Nasafytol® is a standardized combination supplement containing bioactive quercetin (65 mg) and curcumin (42 mg) from Curcuma longa, specifically formulated to enhance bioavailability and provide synergistic benefits. Both quercetin and curcumin in Nasafytol® are optimized for absorption and efficacy, making it a promising intervention for managing inflammatory and immune-related conditions.
The combination of quercetin and curcumin in Nasafytol® is hypothesized to provide synergistic benefits in managing Long COVID-19 symptoms. This pragmatic clinical study aims to evaluate the efficacy of Nasafytol® in reducing symptom burden and improving quality of life in adults experiencing mild to moderate Long COVID-19 symptoms. Participants will receive the combined supplement for two months, with primary outcomes focused on symptom improvement and secondary outcomes assessing changes in quality of life, the need for NSAIDs, and inflammatory markers.
The study is designed as a real-world pragmatic trial to provide evidence of the potential health benefits of Nasafytol® for Long COVID-19, addressing a critical gap in current management strategies.
Quercetin and curcumin, two natural compounds with well-documented anti-inflammatory, antioxidant, and immunomodulatory properties, have gained attention for their potential benefits in various inflammatory and infectious conditions. Quercetin, a flavonoid found in various fruits and vegetables, has been shown to inhibit pro-inflammatory cytokines, reduce oxidative stress, and modulate immune responses. Curcumin, a polyphenol derived from turmeric (Curcuma longa), is known for its strong anti-inflammatory and antioxidant properties and has demonstrated immune-modulating effects in clinical studies.
Nasafytol® is a standardized combination supplement containing bioactive quercetin (65 mg) and curcumin (42 mg) from Curcuma longa, specifically formulated to enhance bioavailability and provide synergistic benefits. Both quercetin and curcumin in Nasafytol® are optimized for absorption and efficacy, making it a promising intervention for managing inflammatory and immune-related conditions.
The combination of quercetin and curcumin in Nasafytol® is hypothesized to provide synergistic benefits in managing Long COVID-19 symptoms. This pragmatic clinical study aims to evaluate the efficacy of Nasafytol® in reducing symptom burden and improving quality of life in adults experiencing mild to moderate Long COVID-19 symptoms. Participants will receive the combined supplement for two months, with primary outcomes focused on symptom improvement and secondary outcomes assessing changes in quality of life, the need for NSAIDs, and inflammatory markers.
The study is designed as a real-world pragmatic trial to provide evidence of the potential health benefits of Nasafytol® for Long COVID-19, addressing a critical gap in current management strategies.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: